Pharmacy Times October 15, 2024
Alana Hippensteele, Managing Editor

Key Takeaways

  • The FDA struggles with regulating AI/ML devices, often underestimating their prevalence and impact in medical devices.
  • Continuous glucose monitors, despite AI/ML integration, follow traditional approval pathways, bypassing AI-specific scrutiny.
  • Ethical concerns arise from AI biases, as studies reveal racial and gender disparities in medical diagnoses.
  • Many AI/ML devices lack transparency and validation, posing challenges for regulatory oversight and public trust.

The FDA faces a multitude of challenges in regulating artificial intelligence (AI) and machine learning (ML) medical devices.

There are a lot of parallels with how the FDA manages the review of devices and drugs, explained Omar Badawi, PharmD, MPH, FCCM, during a presentation at the 2024 American College of Clinical Pharmacy (ACCP) Annual Meeting. However,...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: AI (Artificial Intelligence), FDA, Govt Agencies, Medical Devices, Technology
Related Articles:
The Current State Of Almost 950 FDA-Approved, AI-Based Medical Devices
FDA shakes up weight loss market as Mounjaro shortage ends
Cytovale Secures $100M to Expand Commercialization of FDA-Cleared Sepsis Test
FDA's Promised Guidance on Pulse Oximeters Unlikely to End Decades of Racial Bias
AI explained: AI and FDA device regulation

Share This Article